Amicus Therapeutics, Inc
(NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed dia...

Website: http://www.amicusrx.com

Founded: 2002

Full Time Employees: 584

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-02-04	2013-09-30	2013-06-30	2013-03-31	2013-02-04	2012-09-30	2012-06-30	2012-03-31	2012-02-04	2011-12-31	2011-09-30	2011-06-30	2011-02-04	2010-12-31	2010-09-30	2010-03-31	2010-02-04	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2009-02-04	2008-12-31	2008-06-30	2008-03-31	2008-02-04	2007-12-31	2007-09-30	2007-06-30	2007-02-04

net product sales	185,212,000	169,061,000	154,688,000	125,249,000	149,706,000	141,517,000	126,669,000	110,403,000	115,082,000	103,501,000	94,503,000	86,270,000	88,096,000	81,691,000	80,731,000	78,715,000	82,154,000	79,545,000	77,413,000	66,402,000	70,571,000	67,437,000	62,353,000	60,525,000	55,293,000	48,768,000	44,130,000	34,046,000	32,644,000	20,596,000	21,309,000	16,696,000	10,874,000	7,158,000	4,169,000	2,127,000
yoy	23.72%	19.46%	22.12%	13.45%	30.09%	36.73%	34.04%	27.97%	30.63%	26.70%	17.06%	9.60%	7.23%	2.70%	4.29%	18.54%	16.41%	17.95%	24.15%	9.71%	27.63%	38.28%	41.29%	77.77%	69.38%	136.78%	107.10%	103.92%	200.20%	187.73%	411.13%	684.96%
qoq	9.55%	9.29%	23.50%	-16.34%	5.79%	11.72%	14.73%	-4.07%	11.19%	9.52%	9.54%	-2.07%	7.84%	1.19%	2.56%	-4.19%	3.28%	2.75%	16.58%	-5.91%	4.65%	8.15%	3.02%	9.46%	13.38%	10.51%	29.62%	4.29%	58.50%	-3.35%	27.63%	53.54%	51.91%	71.70%	96.00%
cost of goods sold	26,547,000	19,467,000	15,217,000	11,698,000	14,836,000	13,279,000	11,261,000	13,567,000	11,324,000	9,946,000	9,114,000	6,942,000	9,384,000	13,436,000	8,197,000	7,582,000	7,851,000	11,696,000	8,380,000	6,539,000	9,417,000	8,399,000	6,676,000	6,552,000	6,945,000	5,596,000	5,367,000	4,055,000	2,515,000	4,310,000	3,135,000	2,615,000	1,790,000	1,061,000	775,000	344,000
gross profit	158,665,000	149,594,000	139,471,000	113,551,000	134,870,000	128,238,000	115,408,000	96,836,000	103,758,000	93,555,000	85,389,000	79,328,000	78,712,000	68,255,000	72,534,000	71,133,000	74,303,000	67,849,000	69,033,000	59,863,000	61,154,000	59,038,000	55,677,000	53,973,000	48,348,000	43,172,000	38,763,000	29,991,000	28,300,000	16,286,000	18,174,000	14,081,000	9,084,000	6,097,000	3,394,000	1,783,000
yoy	17.64%	16.65%	20.85%	17.26%	29.99%	37.07%	35.16%	22.07%	31.82%	37.07%	17.72%	11.52%	5.93%	0.60%	5.07%	18.83%	21.50%	14.92%	23.99%	10.91%	26.49%	36.75%	43.63%	79.96%	70.84%	165.09%	113.29%	112.99%	211.54%	167.11%	435.47%	689.74%
qoq	6.06%	7.26%	22.83%	-15.81%	5.17%	11.12%	19.18%	-6.67%	10.91%	9.56%	7.64%	0.78%	15.32%	-5.90%	1.97%	-4.27%	9.51%	-1.72%	15.32%	-2.11%	3.58%	6.04%	3.16%	11.63%	11.99%	11.37%	29.25%	5.98%	73.77%	-10.39%	29.07%	55.01%	48.99%	79.64%	90.35%
gross margin %	85.67%	88.49%	90.16%	90.66%	90.09%	90.62%	91.11%	87.71%	90.16%	90.39%	90.36%	91.95%	89.35%	83.55%	89.85%	90.37%	90.44%	85.30%	89.17%	90.15%	86.66%	87.55%	89.29%	89.17%	87.44%	88.53%	87.84%	88.09%	86.69%	79.07%	85.29%	84.34%	83.54%	85.18%	81.41%	83.83%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%		NaN%	NaN%	NaN%	NaN%	NaN%	NaN%		NaN%	NaN%	NaN%	NaN%		NaN%	NaN%	NaN%		NaN%	NaN%	NaN%
operating expenses:
research and development	23,741,000	23,415,000	60,848,000	27,839,000	30,190,000	26,160,000	24,683,000	28,329,000	35,029,000	40,704,000	35,149,000	41,499,000	63,871,000	52,970,000	78,319,000	81,517,000	85,596,000	59,333,000	63,003,000	64,117,000	79,293,000	70,419,000	69,611,000	89,120,000	91,912,000	58,892,000	70,981,000	64,593,000	57,217,000	138,227,000	34,660,000	40,798,000	40,641,000	31,985,000	30,876,000	32,457,000	18,281,000	23,425,000	20,971,000	17,234,000	16,113,000	12,049,000	9,978,000	367,829,000	10,110,000	10,725,000	11,989,000	327,882,000	11,499,000	13,723,000	14,004,000	279,624,000			11,618,000	237,507,000	13,154,000	8,862,000	8,889,000		10,127,000	12,609,000	13,470,000	11,875,000			8,848,000	6,941,000		5,351,000	7,537,000	6,783,000
selling, general, and administrative	117,081,000	90,036,000	84,543,000	91,827,000	86,668,000	75,106,000	73,576,000	88,029,000	70,239,000	65,651,000	65,423,000	73,957,000	54,274,000	47,272,000	53,379,000	58,116,000	57,601,000	46,107,000	42,276,000	46,726,000	43,685,000	37,850,000	34,657,000	40,215,000	43,300,000	39,680,000	42,578,000
restructuring charges						3,143,000		6,045,000																												11,000	8,000	50,000	7,000	26,000	10,000	15,000		3,502,000				1,522,000				1,522,000				1,522,000
loss on impairment of assets			1,702,000								1,134,000					6,616,000																	465,427,000
depreciation and amortization	1,897,000	1,874,000	1,852,000	1,837,000	2,041,000	2,170,000	2,182,000	2,154,000	2,182,000	2,228,000	2,206,000	1,257,000	1,311,000	1,286,000	1,334,000	1,411,000	1,518,000	1,520,000	1,567,000	1,604,000	2,547,000	2,496,000	2,039,000	1,764,000	1,514,000	1,116,000	1,154,000	991,000														375,000	396,000	13,899,000	429,000	450,000	439,000	12,207,000	422,000	442,000	420,000	10,483,000			426,000	9,342,000	481,000	511,000	536,000		547,000	561,000	519,000	505,000			332,000	321,000		231,000	315,000	312,000
total operating expenses	142,719,000	115,325,000	148,945,000	121,503,000	118,899,000	106,579,000	100,441,000	124,557,000	107,450,000	110,578,000	104,249,000	116,964,000	121,040,000	102,095,000	133,147,000	146,472,000	146,449,000	110,248,000	107,867,000	112,918,000	125,989,000	111,799,000	107,022,000	132,030,000	137,371,000	100,477,000	115,193,000	111,270,000	97,783,000	172,467,000	65,105,000	70,263,000	284,316,000	53,158,000	55,409,000	46,723,000	48,542,000	43,001,000	38,045,000	26,943,000	24,058,000	17,109,000	14,741,000	543,865,000	15,174,000	16,005,000	17,251,000	480,495,000	16,916,000	19,984,000	18,519,000	410,421,000			18,764,000	354,310,000	17,458,000	13,265,000	13,350,000		16,534,000	18,387,000	19,212,000	17,575,000			14,298,000	12,448,000		8,080,500	11,806,000	10,284,000
income from operations	15,946,000	34,269,000	-9,474,000	-7,952,000	15,971,000	21,659,000	14,967,000	-27,721,000	-3,692,000	-17,023,000	-18,860,000	-37,636,000	-42,328,000	-33,840,000	-60,613,000	-75,339,000	-72,146,000	-42,399,000	-38,834,000	-53,055,000	-64,835,000	-52,761,000	-51,345,000	-78,057,000	-89,023,000	-57,305,000	-76,430,000	-81,279,000	-69,483,000	-156,181,000	-46,931,000																								-14,724,000	-262,274,000	-16,536,000	-13,265,000	-13,350,000		32,942,000	-13,474,000	-13,851,000	-12,969,000			-10,491,000	-9,288,000		-8,080,500	-11,806,000	-10,284,000
yoy	-0.16%	58.22%	-163.30%	-71.31%	-532.58%	-227.23%	-179.36%	-26.34%	-91.28%	-49.70%	-68.88%	-50.04%	-41.33%	-20.19%	56.08%	42.00%	11.28%	-19.64%	-24.37%	-32.03%	-27.17%	-7.93%	-32.82%	-3.96%	28.12%	-63.31%	62.86%																												10.29%		-150.20%	-1.55%	-3.62%				32.03%	39.63%			-11.14%	-9.68%
qoq	-53.47%	-461.72%	19.14%	-149.79%	-26.26%	44.71%	-153.99%	650.84%	-78.31%	-9.74%	-49.89%	-11.08%	25.08%	-44.17%	-19.55%	4.43%	70.16%	9.18%	-26.80%	-18.17%	22.88%	2.76%	-34.22%	-12.32%	55.35%	-25.02%	-5.97%	16.98%	-55.51%	232.79%																									-94.39%	1486.08%	24.66%	-0.64%			-344.49%	-2.72%	6.80%				12.95%			-31.56%	14.80%
operating margin %	8.61%	20.27%	-6.12%	-6.35%	10.67%	15.30%	11.82%	-25.11%	-3.21%	-16.45%	-19.96%	-43.63%	-48.05%	-41.42%	-75.08%	-95.71%	-87.82%	-53.30%	-50.16%	-79.90%	-91.87%	-78.24%	-82.35%	-128.97%	-161.00%	-117.51%	-173.19%	-238.73%	-212.85%	-758.31%	-220.24%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%		NaN%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%		Infinity%	-Infinity%	-Infinity%	-Infinity%		NaN%	-Infinity%	-Infinity%		-Infinity%	-Infinity%	-Infinity%
other expense:
interest income	833,000	829,000	843,000	812,000	1,416,000	1,081,000	1,370,000	1,540,000	1,671,000	1,471,000	1,737,000	2,199,000	1,972,000	563,000	356,000	133,000	186,000	108,000	50,000	165,000	328,000	518,000	865,000	1,515,000	2,259,000	2,752,000	2,599,000	2,639,000	3,090,000	2,721,000	2,913,000	1,737,000	1,190,000	753,000	759,000	460,000	331,000	307,000	316,000	158,000	171,000	55,000	36,000	14,605,000	36,000	46,000	65,000	14,454,000	92,000	116,000	27,000	14,100,000			46,000	14,018,000	35,000	33,000	53,000		73,000	129,000	269,000	526,000			1,331,000	1,702,000		836,500	1,593,000	1,060,000
interest expense	-11,428,000	-11,711,000	-11,565,000	-11,455,000	-11,958,000	-12,692,000	-12,512,000	-12,436,000	-12,827,000	-12,986,000	-12,492,000	-11,844,000	-11,095,000	-9,620,000	-8,257,000	-8,147,000	-8,164,000	-8,165,000	-8,150,000	-7,992,000	-8,277,000	-6,784,000	-3,635,000	-3,729,000	-3,767,000	-4,026,000	-4,625,000	-6,454,000	-8,639,000	-4,715,000	-4,560,000																								-41,000	-2,274,000	-57,000	-66,000	-83,000		-123,000	-84,000	-41,000	-29,000			-59,000	-70,000		-67,250	-90,000	-86,000
other income	-2,208,000	10,887,000	1,015,000	550,000	2,505,000	-3,263,000			-2,879,000	3,833,000	-10,902,000	-5,938,000	-18,628,000	13,634,000	7,268,000	1,902,000	-682,250	237,000			-810,000	3,019,000	5,326,000	-8,316,000			-877,000	1,086,000	-2,039,000	-1,039,000	-5,316,000	2,764,000	2,044,000	2,400,000	610,000													252,000		21,000		231,000				231,000
income before income tax	3,143,000	34,274,000			-9,172,500	6,785,000	108,000
income tax expense	-1,453,000	-16,968,000	-5,239,000	-3,641,000			-15,805,000				-2,715,000				-911,000	-3,809,000			-4,525,000	-1,582,000			-3,703,000	-361,000
net income attributable to common stockholders	-7,200,000	17,306,000																																										-414,691,000				-356,573,000				-303,467,000				-271,909,000
yoy																																												16.30%				17.50%				11.61%
qoq	-141.60%
net income margin %	-3.89%	10.24%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	-Infinity%	NaN%	NaN%	NaN%	-Infinity%	NaN%	NaN%	NaN%	-Infinity%		NaN%	NaN%	-Infinity%	NaN%	NaN%	NaN%		NaN%	NaN%	NaN%	NaN%		NaN%	NaN%	NaN%		NaN%	NaN%	NaN%
net income attributable to common stockholders per common share — basic	-22.5	60
net income attributable to common stockholders per common share — diluted	-22.5	60
weighted-average common shares outstanding — basic		308,468,423,000
weighted-average common shares outstanding — diluted		310,433,494,000
loss before income tax			-19,181,000	-18,045,000				-43,583,000	-31,660,000	-24,705,000	-40,517,000	-53,219,000	-70,079,000	-29,263,000	-61,246,000	-81,451,000	-80,296,000	-50,476,000	-46,700,000	-64,082,000	-73,594,000	-63,284,000	-48,789,000	-88,587,000	-89,885,000	-62,060,000	-83,834,000	-120,131,000	-77,071,000	-159,214,000	-61,494,000
net loss attributable to common stockholders			-24,420,000	-21,686,000	14,739,000	-6,729,000	-15,697,000	-48,419,000	-33,843,000	-21,577,000	-43,232,000	-52,932,000	-55,865,000	-33,286,000	-62,157,000	-85,260,000	-83,277,000	-50,294,000	-51,225,000	-65,664,000	-71,401,000	-64,011,000	-52,492,000	-88,948,000	-89,729,000	-61,809,000	-84,551,000	-120,299,000	-78,081,000	-159,163,000	-61,833,000	-49,916,000	-111,666,000	-48,136,000	-54,992,000										-14,589,000	-15,349,000	-17,458,000		-16,290,000	-9,343,000	-13,137,000				-12,641,000		-15,088,000	-15,357,000	-13,176,000		32,956,000	-13,429,000	-13,623,000	-12,472,000			-9,294,000	-7,731,000		-7,436,250	-10,303,000	-9,706,000
net loss attributable to common stockholders per common share — basic and diluted			-80	-70	50	-20	-50	-160	-110	-70	-150	-180	-190	-120	-210	-300	-290	-190	-190	-250	-270	-250	-200	-350	-350	-240	-360	-560	-410	-840	-330	-280	-690	-340	-390												-350				-350						-480	-560	-540		1,460	-590	-600	-550			-410
weighted-average common shares outstanding — basic and diluted	308,363,768,000		308,254,256,000	307,689,207,000	304,380,502,000	304,690,596,000	303,773,922,000	302,903,009,000	295,164,515,000	295,759,435,000	292,797,002,000	291,336,750,000	289,057,198,000	289,223,709,000	291,970,562,000	288,481,741,000	271,421,986,000	267,464,637,000	266,398,516,000	264,369,317,000	258,867,380,000	259,161,799,000	257,973,329,000	256,968,248,000	240,421,001,000	254,674,422,000	238,089,824,000	213,519,287,000	185,790,000	189,162,841,000	188,621,423,000	175,977,700,000	160,796,841,000	143,000,718,000	142,770,629,000	140,656,109,000	129,122,175,000		118,724,882,000	99,994,125,000	95,743,416,000	78,889,346,000	67,212,764,000		49,621,188,000	49,621,188,000	49,621,188,000		48,513,647,000	46,870,067,000	37,887,520,000				34,530,693,000		27,734,797,000	27,625,137,000	24,289,422,000		22,624,134,000	22,621,513,000	22,618,026,000	22,613,850,000		22,493,803,000	22,467,198,000			13,235,755,000
changes in fair value of contingent consideration payable										1,995,000	337,000	251,000	1,584,000	567,000	115,000	-1,188,000	1,734,000	3,288,000	1,021,000	471,000	464,000	1,034,000	715,000	931,000	645,000	789,000	480,000	1,383,000	600,000	1,300,000	300,000	1,100,000		1,050,000	4,578,000		10,186,000	3,152,000	1,300,000	100,000	1,000,000			505,000
income tax benefit					6,805,000	-13,514,000		-4,836,000	-2,183,000	3,128,000		287,000	14,214,000	-4,023,000			-1,481,250	182,000			2,193,000	-727,000			156,000	251,000	-717,000	-168,000	-1,010,000	51,000	-339,000	1,392,000	164,683,000			253,000	453,000							12,220,000				8,708,000
other expense							-3,717,000	-4,966,000											234,000	-3,200,000					-818,000	-3,481,000
other income:
loss on extinguishment of debt																		-257,000				-7,276,000																		952,000
loss on exchange of convertible notes																											-4,501,000	-36,123,000
revenue:
change in fair value of derivatives																															-7,600,000	4,861,000
selling, general and administrative																												44,303,000	38,765,000	31,867,000	29,172,000	27,396,000	21,647,000	19,311,000	19,132,000	17,469,000
depreciation																													753,750	1,073,000	973,000	969,000	851,000	812,000	823,000	896,000	767,000	673,000	395,000	353,000	508,000
loss before income tax benefit
net income																																							-37,800,000	-27,133,000	-24,288,000	-17,149,000	-14,614,000												-12,641,000	-251,683,000	-15,088,000	-15,357,000	-13,176,000		32,956,000	-13,429,000	-13,623,000	-12,472,000			-9,294,000	-7,731,000		-11,773,000	-10,303,000	-9,396,000
net loss per common share — basic and diluted																																				-330
general and administrative																																					19,300,000	15,701,000	15,372,000	8,278,000	6,427,000	5,270,000	4,753,000	156,682,000	4,635,000	4,830,000	4,823,000	137,436,000	4,995,000	5,819,000	4,095,000	117,344,000			6,720,000	104,491,000	3,823,000	3,892,000	3,925,000		4,338,000	5,217,000	5,223,000	5,195,000			5,118,000	5,186,000		2,498,500	3,954,000	3,189,000
net loss per common shares — basic and diluted																																					-400		-320	-270	-250	-220	-220
net loss attributable to common stockholders per common shares – basic and diluted																																						-350
weighted-average common shares outstanding – basic and diluted																																						125,178,517,000																														22,412,689,000			22,291,832,000	7,083,748,000
research revenue																																										293,000	475,000	58,312,000	39,000			57,493,000		5,477,000	6,114,000	52,016,000			2,380,000	37,794,000					4,746,000	4,219,000	4,667,000	3,912,000			3,113,000	2,466,000
total revenue																																										293,000	475,000	122,694,000	39,000			121,875,000		10,637,000	7,774,000	111,238,000			4,040,000	92,036,000					49,476,000	4,913,000	5,361,000	4,606,000			3,807,000	3,160,000
change in fair value of warrant liability																																												2,461,000	517,000	619,000		1,291,000	553,000						2,078,000	-3,218,000	-946,000	-2,059,000	204,000											-37,250		-86,000
collaboration and milestone revenue																																												64,382,000				64,382,000		5,160,000
impairment of leasehold improvements																																												1,030,000				1,030,000				1,030,000				1,030,000
in-process research and development																																												418,000				418,000				418,000				418,000
other (expense)/ income																																												243,000
income before tax benefit																																																								-253,517,000
deemed dividend																																																								-19,424,000
preferred stock accretion																																																								-802,000														-87,750		-310,000
net income attributable to common stockholders per common share — basic and diluted
loss before tax benefit																																																							-12,641,000		-16,227,000	-15,357,000	-13,176,000		32,956,000	-13,429,000	-13,623,000	-12,472,000			-9,219,000	-7,656,000		-7,348,500	-10,303,000	-9,396,000
net loss attributable to common stockholders per common shares — basic and diluted																																													-290	-310			-340	-200					-370
benefit from income taxes																																																				5,463,000				1,834,000											-75,000	-75,000
collaboration revenue																																																			1,660,000	59,222,000			1,660,000	54,242,000					44,730,000	694,000	694,000	694,000			694,000	694,000
net income attributable to common stockholders per common shares — basic and diluted
net loss attributable to common stockholders per common share – basic and diluted																																																																				-340		-730	-460	-1,370

Balance Sheets:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-09-30	2015-06-30	2015-03-31	2014-09-30	2014-06-30	2014-03-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2006-12-31

assets
current assets:
cash and cash equivalents	214,010,000	190,553,000	158,702,000	181,657,000	213,752,000	233,647,000	209,335,000	209,761,000	246,994,000	263,320,000	211,307,000	160,602,000	148,813,000	277,592,000	235,639,000	233,317,000	245,197,000	385,903,000	176,538,000	184,833,000	163,240,000	210,631,000	164,573,000	123,231,000	142,837,000	166,319,000	220,578,000	96,349,000	79,749,000	201,827,000	73,311,000	114,322,000	64,133,000	37,394,000	44,755,000	33,115,000	63,656,000	23,510,000	19,439,000	249,023,000	28,827,000	19,671,000	41,904,000	27,533,000	30,047,000	23,476,000	26,736,000	24,273,000	28,858,000	24,523,000		22,810,000	25,789,000	27,662,000	29,572,000	22,097,000	24,622,000	33,562,000	19,339,000	20,487,000	15,760,000	23,242,000	28,073,000	19,855,000	12,315,000	18,203,000	44,188,000	19,933,000	26,494,000
investments in marketable securities	79,526,000	73,290,000	72,296,000	68,916,000	36,194,000	16,110,000	50,727,000	29,842,000	39,206,000	16,980,000	54,319,000	106,507,000	144,782,000	77,108,000	151,202,000	177,878,000	237,299,000	171,057,000	206,530,000	232,596,000	320,029,000	298,451,000	145,017,000	215,642,000	309,903,000	347,875,000	355,078,000	341,978,000	424,403,000	362,556,000	465,641,000	448,198,000	15,109,000	189,838,000	235,087,000	179,284,000	150,494,000	142,341,000	217,070,000	112,396,000	119,940,000	65,511,000	36,092,000	44,121,000	30,448,000	50,700,000	58,015,000	81,942,000	66,914,000	83,673,000		46,718,000	57,257,000	66,112,000	77,873,000	35,484,000	44,444,000	47,870,000	58,885,000	68,784,000	84,670,000	85,806,000	93,051,000	116,400,000	132,635,000	136,355,000	117,339,000	99,475,000	99,229,000
accounts receivable	115,307,000	113,838,000	105,849,000	88,323,000	101,099,000	98,073,000	85,174,000	76,433,000	87,632,000	73,331,000	63,716,000	68,178,000	66,196,000	52,303,000	52,556,000	52,421,000	52,672,000	51,427,000	49,172,000	44,931,000	46,923,000	44,828,000	43,040,000	40,555,000	33,284,000	33,731,000	28,709,000	22,960,000	21,962,000	14,189,000	15,077,000	10,836,000	5,974,000	3,786,000	1,875,000	864,000
inventories	228,819,000	177,928,000	154,875,000	132,412,000	118,782,000	115,338,000	81,320,000	60,759,000	59,696,000	56,936,000	51,381,000	27,004,000	23,816,000	13,272,000	20,879,000	24,324,000	26,818,000	22,072,000	24,086,000	18,801,000	19,556,000	15,767,000	12,979,000	12,831,000	14,041,000	9,154,000	10,395,000	8,167,000	8,390,000	6,311,000	7,769,000	8,070,000	7,272,000	3,948,000	3,698,000	3,251,000	194,000
prepaid expenses and other current assets	38,511,000	38,457,000	46,285,000	39,491,000	34,909,000	35,306,000	35,145,000	54,444,000	49,533,000	52,689,000	52,099,000	37,406,000	40,209,000	38,264,000	37,367,000	30,960,000	34,848,000	20,081,000	24,176,000	21,730,000	29,721,000	15,600,000	18,275,000	15,690,000	20,008,000	19,578,000	20,116,000	13,592,000	16,592,000	16,151,000	14,432,000	10,607,000	6,246,000	6,023,000	10,792,000	5,198,000	3,330,000	2,662,000	3,544,000	3,578,000	2,484,000	1,762,000	951,000	1,758,000	1,692,000	1,978,000	1,753,000	3,077,000	2,658,000	2,789,000		3,038,000	3,076,000	2,304,000	2,236,000	2,897,000	2,081,000	2,504,000	2,262,000	4,305,000	2,653,000	1,984,000	2,463,000	1,990,000	1,671,000	1,076,000	1,513,000	1,245,000	1,432,000
total current assets	676,173,000	594,066,000	538,007,000	510,799,000	504,736,000	498,474,000	461,701,000	431,239,000	483,061,000	463,256,000	432,822,000	399,697,000	423,816,000	458,539,000	497,643,000	518,900,000	596,834,000	650,540,000	480,502,000	502,891,000	579,469,000	585,277,000	383,884,000	407,949,000	520,073,000	576,657,000	634,876,000	483,046,000	551,096,000	601,034,000	576,230,000	592,033,000	431,013,000	240,989,000	296,207,000	221,712,000	217,674,000	168,513,000	240,053,000	364,997,000	151,251,000	87,237,000	79,422,000	73,450,000	64,308,000	77,178,000	87,812,000	112,476,000	105,667,000	115,286,000		76,394,000	88,099,000	100,047,000	109,681,000	60,478,000	71,147,000	83,936,000	80,486,000	93,576,000	103,083,000	111,032,000	123,587,000	138,245,000	146,621,000	155,634,000	163,040,000	120,653,000	127,155,000
operating lease right-of-use assets	21,138,000	21,549,000	21,988,000	22,138,000	22,278,000	23,144,000	22,611,000	23,003,000	26,312,000	29,511,000	28,042,000	28,483,000	29,534,000	29,871,000	30,447,000	27,509,000	20,586,000	21,270,000
property and equipment, less accumulated depreciation of 31,821 and 28,775 at december 31, 2025 and 2024, respectively	27,108,000
intangible assets, less accumulated amortization of 9,085 and 5,802 at december 31, 2025 and 2024, respectively	13,915,000
goodwill	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	197,797,000	207,564,000	11,613,000	11,613,000	11,613,000	11,613,000	11,613,000
other non-current assets	13,739,000	12,897,000	13,371,000	13,998,000	13,641,000	18,678,000	17,361,000	17,657,000	18,553,000	21,130,000	19,049,000	20,172,000	19,242,000	17,872,000	18,045,000	25,188,000	24,427,000	22,077,000	21,200,000	20,538,000	19,095,000	26,453,000	25,876,000	29,414,000	28,317,000	14,351,000	12,035,000	11,265,000	6,683,000	6,099,000	5,915,000	5,592,000	4,219,000	3,009,000	2,932,000	1,788,000	1,657,000	1,484,000	982,000	924,000	892,000	508,000	515,000	546,000	442,000	442,000	442,000	442,000	442,000	442,000		714,000	267,000	267,000	267,000	267,000	267,000	267,000	485,000	267,000	267,000	267,000	267,000	504,000	267,000	267,000	267,000	267,000	267,000
total assets	949,870,000	868,811,000	815,303,000	789,839,000	785,033,000	786,557,000	749,484,000	721,789,000	777,880,000	764,084,000	730,093,000	700,519,000	724,167,000	759,528,000	800,589,000	826,938,000	905,140,000	956,675,000	786,892,000	810,034,000	886,520,000	900,542,000	701,451,000	738,349,000	850,207,000	882,292,000	918,033,000	764,702,000	789,951,000	838,589,000	825,889,000	870,005,000	680,779,000	938,966,000	993,381,000	918,180,000	914,006,000	862,907,000	986,692,000	403,913,000	192,616,000	125,487,000	117,994,000	112,357,000	69,106,000	82,335,000	93,216,000	118,211,000	111,598,000	120,801,000	69,795,000	78,867,000	90,288,000	102,551,000	112,552,000	63,762,000	74,886,000	88,137,000	85,370,000	98,892,000	108,676,000	116,375,000	128,773,000	143,165,000	151,083,000	159,532,000	167,097,000	124,833,000	131,583,000	59,645,000
liabilities and stockholders' equity
current liabilities:
accounts payable	28,630,000	19,103,000	13,893,000	14,451,000	12,947,000	13,481,000	32,057,000	9,210,000	15,120,000	23,154,000	13,522,000	24,965,000	15,413,000	12,046,000	23,113,000	22,914,000	21,513,000	24,474,000	13,762,000	16,110,000	17,063,000	14,764,000	14,306,000	16,239,000																																										1,050,000	530,000	535,000	338,000
accrued expenses and other current liabilities	200,457,000	171,165,000	145,144,000	129,877,000	127,300,000	136,116,000	127,897,000	124,622,000	144,245,000	138,535,000	124,868,000	92,747,000	93,636,000	125,235,000	114,703,000	80,379,000	98,153,000	72,453,000	71,325,000	57,178,000	96,841,000	89,595,000	85,478,000	66,722,000
operating lease liabilities	8,741,000	8,662,000	8,610,000	8,562,000	8,455,000	8,541,000	8,112,000	8,270,000	8,324,000	7,765,000	7,840,000	8,005,000	8,552,000	7,536,000	7,543,000	7,255,000	7,409,000	7,175,000	7,106,000	6,764,000	6,872,000	7,368,000	8,516,000	7,503,000	7,189,000	6,356,000	2,678,000
total current liabilities	237,828,000	198,930,000	167,647,000	152,890,000	148,702,000	158,138,000	168,066,000	142,102,000	167,689,000	169,454,000	159,235,000	138,385,000	139,018,000	164,650,000	164,625,000	129,699,000	145,975,000	121,102,000	111,993,000	99,652,000	129,676,000	111,727,000	108,300,000	91,714,000	128,812,000	93,081,000	89,547,000	65,869,000	86,125,000	65,880,000	52,963,000	140,705,000	68,159,000	100,683,000	109,596,000	85,612,000	80,459,000	64,427,000	35,865,000	16,901,000	21,022,000	13,824,000	11,171,000	9,366,000	8,598,000	9,967,000	7,995,000	9,930,000	17,812,000	17,765,000		18,625,000	16,878,000	16,636,000	16,223,000	8,148,000	7,147,000	8,838,000	11,193,000	17,082,000	15,237,000	12,554,000	13,378,000	14,937,000	15,298,000	14,810,000	15,793,000	9,571,000	6,965,000
long-term debt	392,660,000	391,985,000	391,322,000	390,708,000	390,111,000	389,494,000	388,939,000	388,391,000	387,858,000	394,071,000	393,350,000	392,658,000	391,990,000	391,319,000	390,652,000	389,994,000	389,357,000	388,719,000	390,434,000	389,789,000	389,254,000	388,584,000
other non-current liabilities	4,179,000	5,298,000	8,647,000	8,487,000	7,097,000	13,477,000	12,949,000	12,771,000	13,282,000	8,962,000	9,045,000	9,648,000	8,939,000	8,146,000	8,207,000	7,335,000	6,801,000	6,823,000	6,535,000	6,268,000	6,379,000	4,817,000	4,511,000	4,214,000	5,296,000	4,591,000	3,987,000	3,609,000	2,853,000	3,029,000						1,816,000	1,735,000	1,061,000	555,000
total liabilities	675,629,000	638,387,000	610,999,000	596,281,000	590,988,000	607,732,000	616,961,000	591,095,000	617,706,000	630,847,000	618,512,000	597,946,000	601,120,000	626,963,000	627,164,000	588,321,000	597,771,000	580,046,000	572,982,000	559,138,000	600,140,000	580,273,000	340,498,000	335,755,000	373,782,000	334,025,000	317,975,000	313,034,000	447,039,000	427,638,000	263,994,000	348,388,000																			40,203,000																			13,071,000
commitments and contingencies
stockholders' equity:
common stock, 0.01 par value...	3,037,000	3,017,000	3,016,000	3,016,000	2,944,000	2,942,000	2,923,000	2,922,000	2,918,000	2,890,000	2,856,000	2,820,000	2,815,000	2,813,000	2,811,000	2,809,000	2,808,000	2,805,000	2,685,000	2,680,000	2,650,000	2,626,000	2,614,000	2,607,000		2,591,000	2,589,000	2,347,000		1,941,000	1,939,000	1,929,000	1,707,000	1,485,000	1,482,000
common stock in treasury, at cost; 7,390 shares as of december 31, 2025	-71,000
additional paid-in capital	3,014,456,000	2,973,625,000	2,956,839,000	2,939,673,000	2,926,115,000	2,905,760,000	2,868,925,000	2,853,550,000	2,836,018,000	2,787,275,000	2,733,148,000	2,691,836,000	2,664,744,000	2,645,372,000	2,631,110,000	2,617,935,000	2,595,419,000	2,579,953,000	2,364,494,000	2,350,507,000	2,308,578,000	2,274,797,000	2,250,849,000	2,238,346,000	2,227,225,000	2,210,890,000	2,201,447,000	1,970,607,000	1,740,061,000	1,731,174,000	1,723,865,000	1,621,479,000	1,387,767,000	1,132,229,000	1,126,148,000	1,038,613,000	990,032,000	921,234,000	914,263,000	826,582,000	574,757,000	468,650,000	444,600,000	424,844,000	392,213,000	390,696,000	389,113,000	385,042,000	365,210,000	363,456,000		297,849,000	295,898,000	291,696,000	290,248,000	260,747,000	259,266,000	257,787,000	242,259,000	240,499,000	238,492,000	236,397,000	234,412,000	232,701,000	230,922,000	229,035,000	227,438,000	226,246,000	225,027,000
accumulated other comprehensive gain:
foreign currency translation adjustment	24,120,000	22,886,000	30,935,000	12,941,000	5,302,000	25,159,000	8,991,000	6,847,000	5,429,000	-6,573,000	4,337,000	-6,543,000	-11,989,000	-38,724,000	-16,603,000	-420,000	5,251,000	6,617,000	9,255,000	9,020,000	8,412,000	4,576,000	4,865,000	6,981,000	2,785,000	1,156,000	352,000	-1,309,000	495,000	-875,000	-1,539,000
unrealized loss on available-for-sale securities	-11,000	-53,000	-129,000	-135,000	-207,000	-188,000	-197,000	-203,000	-188,000	-195,000	-177,000	-201,000	-116,000	-354,000	-637,000	-608,000		-184,000	-173,000	-185,000
warrants					71,000	71,000	71,000	71,000	71,000	71,000	71,000	83,000	83,000	83,000	83,000	83,000	83,000	83,000			12,387,000	12,387,000	12,387,000	12,387,000	12,387,000	12,387,000	12,387,000	12,387,000	13,063,000	13,063,000	13,063,000	16,076,000	16,076,000	16,076,000	16,076,000	16,076,000	16,076,000	12,298,000
accumulated deficit	-2,767,290,000	-2,768,980,000	-2,786,286,000	-2,761,866,000	-2,740,180,000	-2,754,919,000	-2,748,190,000	-2,732,493,000	-2,684,074,000	-2,650,231,000	-2,628,654,000	-2,585,422,000	-2,532,490,000	-2,476,625,000	-2,443,339,000	-2,381,182,000	-2,295,922,000	-2,212,645,000	-2,162,351,000	-2,111,126,000	-2,045,462,000	-1,974,061,000	-1,910,050,000	-1,857,558,000	-1,768,610,000	-1,678,881,000	-1,617,072,000	-1,532,521,000	-1,412,222,000	-1,334,141,000	-1,174,978,000
total stockholders' equity	274,241,000				194,045,000				160,174,000				123,047,000				307,369,000				286,380,000				476,425,000				342,912,000
total liabilities and stockholders' equity	949,870,000				785,033,000				777,880,000				724,167,000				905,140,000				886,520,000				850,207,000				789,951,000																																								131,583,000
property and equipment, less accumulated depreciation of 31,271 and 28,775 at september 30, 2025 and december 31, 2024, respectively		27,759,000
intangible assets, less accumulated amortization of 8,257 and 5,802 at september 30, 2025 and december 31, 2024, respectively		14,743,000
liabilities and stockholders’ equity
stockholders’ equity:
common stock in treasury, at cost; 7,390 shares as of september 30, 2025		-71,000
accumulated other comprehensive income:
total stockholders’ equity		230,424,000	204,304,000	193,558,000		178,825,000	132,523,000	130,694,000		133,237,000	111,581,000	102,573,000		132,565,000	173,425,000	238,617,000		376,629,000	213,910,000	250,896,000		320,269,000	360,953,000	402,594,000		548,267,000	600,058,000	451,668,000		410,951,000	561,895,000	521,617,000	409,680,000	266,892,000	310,778,000	336,555,000	334,243,000	311,632,000	378,755,000	328,902,000	104,010,000	43,277,000	36,308,000	31,084,000	26,489,000	39,559,000	53,337,000	76,759,000	73,167,000	80,776,000	29,592,000	36,789,000	44,607,000	53,061,000	64,934,000	50,491,000	64,362,000	74,194,000	71,833,000	37,162,000	48,641,000	60,257,000	71,043,000	83,015,000	89,666,000	97,685,000
total liabilities and stockholders’ equity		868,811,000	815,303,000	789,839,000		786,557,000	749,484,000	721,789,000		764,084,000	730,093,000	700,519,000		759,528,000	800,589,000	826,938,000		956,675,000	786,892,000	810,034,000		900,542,000	701,451,000	738,349,000		882,292,000	918,033,000	764,702,000		838,589,000	825,889,000	870,005,000	680,779,000	938,966,000	993,381,000	918,180,000	914,006,000	862,907,000	986,692,000	403,913,000	192,616,000	125,487,000	117,994,000	112,357,000	69,106,000	82,335,000	93,216,000	118,211,000	111,598,000	120,801,000		78,867,000	90,288,000	102,551,000	112,552,000	63,762,000	74,886,000	88,137,000	85,370,000	98,892,000	108,676,000	116,375,000	128,773,000	143,165,000	151,083,000	159,532,000		124,833,000
property and equipment, less accumulated depreciation of 30,991 and 28,775 at june 30, 2025 and december 31, 2024, respectively			28,570,000
intangible assets, less accumulated amortization of 7,430 and 5,802 at june 30, 2025 and december 31, 2024, respectively			15,570,000
common stock in treasury, at cost; 7,390 shares as of june 30, 2025			-71,000
property and equipment, less accumulated depreciation of 29,842 and 28,775 at march 31, 2025 and december 31, 2024, respectively				28,718,000
intangible assets, less accumulated amortization of 6,611 and 5,802 at march 31, 2025 and december 31, 2024, respectively				16,389,000
common stock in treasury, at cost; 7,390 shares as of march 31, 2025				-71,000
property and equipment, less accumulated depreciation of 28,775 and 25,429 at december 31, 2024 and 2023, respectively					29,383,000
intangible assets, less accumulated amortization of 5,802 and 2,510 at december 31, 2024 and december 31, 2023, respectively					17,198,000
property and equipment, less accumulated depreciation of 29,324 and 25,429 at september 30, 2024 and december 31, 2023, respectively						30,438,000
intangible assets, less accumulated amortization of 4,974 and 2,510 at september 30, 2024 and december 31, 2023, respectively						18,026,000
property and equipment, less accumulated depreciation of 27,844 and 25,429 at june 30, 2024 and december 31, 2023, respectively							31,161,000
intangible assets, less accumulated amortization of 4,147 and 2,510 at june 30, 2024 and december 31, 2023, respectively							18,853,000
property and equipment, less accumulated depreciation of 26,563 and 25,429 at march 31, 2024 and december 31, 2023, respectively								32,421,000
intangible assets, less accumulated amortization of 3,328 and 2,510 at march 31, 2024 and december 31, 2023, respectively								19,672,000
accumulated other comprehensive loss:
property and equipment, less accumulated depreciation of 25,429 and 22,281 at december 31, 2023 and 2022, respectively									31,667,000
intangible assets, less accumulated amortization of 2,510 and 0 at december 31, 2023 and december 31, 2022, respectively									20,490,000
contingent consideration payable											13,005,000	12,668,000	21,417,000	19,833,000	19,266,000	19,151,000	18,900,000	17,000,000	19,800,000	19,600,000	8,900,000	16,561,000	20,027,000	23,612,000	22,681,000	22,036,000	21,247,000	20,767,000		8,800,000	8,600,000	8,700,000	12,900,000	219,162,000	218,199,000					11,800,000	11,700,000	10,200,000	10,800,000	11,105,000
property and equipment, less accumulated depreciation of 25,018 and 22,281 at september 30, 2023 and december 31, 2022, respectively										31,072,000
intangible assets, less accumulated amortization of 1,682 and 0 at september 30, 2023 and december 31, 2022, respectively										21,318,000
deferred reimbursements										5,906,000	5,906,000	5,906,000	4,656,000	5,906,000	5,906,000	5,906,000	5,906,000	7,406,000	7,406,000	7,406,000	7,406,000	8,906,000	8,906,000	1,250,000	1,250,000	5,250,000	2,750,000	2,750,000	5,500,000	2,750,000	2,750,000	7,750,000	16,906,000	16,906,000	21,906,000	35,756,000	35,756,000	35,756,000	36,620,000	36,620,000	36,620,000	36,677,000	36,677,000	36,677,000	34,019,000	32,709,000	31,685,000
deferred income taxes													4,939,000	4,930,000	4,930,000	4,930,000	4,930,000	4,896,000	4,896,000	4,896,000	4,896,000	5,051,000	5,051,000	5,051,000	5,051,000	6,465,000	6,465,000	6,465,000	6,465,000	6,465,000	6,465,000	6,465,000	9,186,000	173,869,000	173,820,000
property and equipment, less accumulated depreciation of 24,060 and 22,281 at june 30, 2023 and december 31, 2022, respectively											30,238,000
intangible assets, less accumulated amortization of 855 and 0 at june 30, 2023 and december 31, 2022, respectively											22,145,000
property and equipment, less accumulated depreciation of 22,901 and 22,281 at march 31, 2023 and december 31, 2022, respectively												31,406,000
intangible assets, less accumulated amortization of 36 and 0 at march 31, 2023 and december 31, 2022, respectively												22,964,000
property and equipment, less accumulated depreciation of 22,281 and 19,882 at december 31, 2022 and 2021, respectively													30,778,000
in-process research & development													23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000	486,700,000	486,700,000	486,700,000	486,700,000	486,700,000	518,810,000	23,000,000	23,000,000	23,000,000	23,000,000	23,000,000
property and equipment, less accumulated depreciation of 23,337 and 19,882 at september 30, 2022 and december 31, 2021, respectively														32,449,000
property and equipment, less accumulated depreciation of 22,188 and 19,882 at june 30, 2022 and december 31, 2021, respectively															33,657,000
property and equipment, less accumulated depreciation of 20,966 and 19,882 at march 31, 2022 and december 31, 2021, respectively																34,544,000
property and equipment, less accumulated depreciation of 19,882 and 14,487 at december 31, 2021 and december 31, 2020, respectively																	42,496,000
unrealized loss on available-for securities																	-270,000												-427,000
property and equipment, less accumulated depreciation of 18,789 and 14,487 at september 30, 2021 and december 31, 2020, respectively																		41,991,000
operating lease right-of-use assets, less accumulated amortization of 8,150 and 7,574 at june 30, 2021 and december 31, 2020, respectively																			22,028,000
property and equipment, less accumulated depreciation of 17,410 and 14,487 at june 30, 2021 and december 31, 2020, respectively																			42,365,000
operating lease right-of-use assets, less accumulated amortization of 7,499 and 7,574 at march 31, 2021 and december 31, 2020, respectively																				22,363,000
property and equipment, less accumulated depreciation of 15,961 and 14,487 at march 31, 2021 and december 31, 2020, respectively																				43,445,000
operating lease right-of-use assets, less accumulated amortization of 7,574 and 5,342 at december 31, 2020 and december 31, 2019, respectively																					23,296,000
property and equipment, less accumulated depreciation of 14,487 and 17,604 at december 31, 2020 and december 31, 2019, respectively																					43,863,000
unrealized gain on available-for securities																					-185,000				40,000									31,000	185,000
operating lease right-of-use assets, less accumulated amortization of 6,850 and 5,342 at september 30, 2020 and december 31, 2019, respectively																						23,397,000
property and equipment, less accumulated depreciation of 23,582 and 17,604 at september 30, 2020 and december 31, 2019, respectively																						44,618,000
unrealized gain on available-for-sale securities																						-56,000	288,000	-169,000		124,000	355,000	157,000		-211,000	-455,000
operating lease right-of-use assets, less accumulated amortization of 6,219 and 5,342 at june 30, 2020 and december 31, 2019, respectively																							23,949,000
property and equipment, less accumulated depreciation of 21,194 and 17,604 at june 30, 2020 and december 31, 2019, respectively																							46,945,000
convertible notes																							2,203,000	2,167,000	2,131,000	2,096,000	2,070,000	22,052,000	175,006,000	172,186,000	169,440,000	166,768,000	161,635,000	159,171,000	156,859,000
senior secured term loan																							147,834,000	147,569,000	147,374,000	147,164,000	146,994,000	146,766,000	146,734,000	146,622,000
operating lease right-of-use assets, less accumulated amortization of 6,260 and 5,342 at march 31, 2020 and december 31, 2019, respectively																								32,501,000
property and equipment, less accumulated depreciation of 19,260 and 17,604 at march 31, 2020 and december 31, 2019, respectively																								47,688,000
operating lease right-of-use assets, less accumulated amortization of 5,342 and 0 at december 31, 2019 and december 31, 2018, respectively																									33,315,000
property and equipment, less accumulated depreciation of 17,604 and 15,671 at december 31, 2019 and december 31, 2018, respectively																									47,705,000
accounts payable, accrued expenses, and other current liabilities																									120,373,000	81,475,000	84,119,000	60,596,000	80,625,000	54,330,000	41,613,000	43,678,000	53,709,000	35,645,000	39,645,000
common stock, .01 par value...																									2,598,000				1,942,000							1,478,000	1,399,000	1,308,000	1,304,000	1,241,000	1,024,000	853,000	789,000	703,000	556,000	556,000	556,000	554,000	524,000	524,000		407,000	406,000	406,000	406,000	337,000	337,000	337,000	287,000	287,000	287,000	287,000	287,000	285,000	285,000	285,000	285,000	284,000	283,000
operating lease right-of-use assets, less accumulated amortization of 2,420 and 0 at september 30, 2019 and december 31, 2018, respectively																										35,814,000
property and equipment, less accumulated depreciation of 17,907 and 15,671 at september 30, 2019 and december 31, 2018, respectively																										34,673,000
operating lease right-of-use assets, less accumulated amortization of 2,641 and 0 at june 30, 2019 and december 31, 2018, respectively																											35,052,000
property and equipment, less accumulated depreciation of 16,890 and 15,671 at june 30, 2019 and december 31, 2018, respectively																											15,273,000
operating and finance lease right-of-use assets, less accumulated amortization of 2,111 and 0 at march 31, 2019 and december 31, 2018, respectively																												36,308,000
property and equipment, less accumulated depreciation of 15,794 and 15,671 at march 31, 2019 and december 31, 2018, respectively																												13,286,000
operating and finance lease liabilities																												2,523,000
property and equipment, less accumulated depreciation of 15,671 and 12,515 at december 31, 2018 and 2017, respectively																													11,375,000
property and equipment, less accumulated depreciation of 15,483 and 12,515 at september 30, 2018 and december 31, 2017, respectively																														10,659,000
property and equipment, less accumulated depreciation of 14,415 and 12,515 at june 30, 2018 and december 31, 2017, respectively																															9,111,000
other non-current liability																															2,770,000	2,494,000	2,313,000	2,283,000	2,223,000					504,000	870,000	514,000	748,000	723,000
property and equipment, less accumulated depreciation of 13,461 and 12,515 at march 31, 2018 and december 31, 2017, respectively																																8,910,000
derivative liability																																80,577,000
investments in marketable securities, current portion																																	347,388,000
property and equipment, less accumulated depreciation of 13,273 and 12,495 at september 30, 2017 and december 31, 2016, respectively																																	9,641,000
deferred reimbursements, current portion																																	6,250,000	18,850,000	13,850,000
contingent consideration payable, current portion																																	8,200,000	46,188,000	56,101,000	55,992,000	56,000,000
property and equipment, less accumulated depreciation of 13,951 and 12,495 at june 30, 2017 and december 31, 2016, respectively																																		10,471,000
foreign currency translation adjustment, less tax expense of 1,293 at june 30, 2017 and december 31, 2016
property and equipment, less accumulated depreciation of 13,316 and 12,495 at march 31, 2017 and december 31, 2016, respectively																																			9,745,000
foreign currency translation adjustment, less tax expense of 1,293 at march 31, 2017 and december 31, 2016																																			1,487,000
assets:
property and equipment, less accumulated depreciation of 15,181 and 13,353 at september 30, 2016 and december 31, 2015, respectively																																				10,183,000
accounts payable and accrued expenses																																				29,013,000	23,828,000	22,501,000	30,565,000	16,901,000	15,833,000	11,331,000	9,918,000	9,167,000	8,166,000	9,018,000	6,427,000	9,428,000	9,067,000	8,449,000		8,098,000	7,019,000	7,418,000	8,290,000	6,809,000	5,752,000	7,358,000	9,635,000	12,759,000	10,988,000	8,683,000	8,796,000	9,804,000	10,745,000
other current liabilities																																				607,000	631,000
due to related party																																				44,047,000	43,443,000	38,509,000	50,000,000
unsecured notes payable																																				21,977,000	21,851,000
contingent consideration payable, less current portion																																				216,198,000	220,300,000	235,303,000	277,684,000
deferred tax liability																																				176,219,000	176,219,000	176,219,000	207,213,000	9,186,000	9,186,000	9,186,000	9,186,000	9,186,000
foreign currency translation adjustment, less tax benefit of 706 at september 30, 2016																																				1,062,000
unrealized gain/ (loss) on available-for securities																																				287,000	201,000	114,000
property and equipment, less accumulated depreciation of 14,284 and 13,353 at june 30, 2016 and december 31, 2015, respectively																																					10,178,000
foreign currency translation adjustment, less tax benefit of 453 at june 30, 2016																																					842,000
property and equipment, less accumulated depreciation of 13,996 and 13,353 at march 31, 2016 and december 31, 2015, respectively																																						8,413,000
current portion of contingent consideration payable																																						41,926,000	5,300,000
property and equipment, less accumulated depreciation of 12,776 and 11,520 at september 30, 2015 and december 31, 2014, respectively																																							3,855,000
current portion of secured loan																																									5,189,000	2,493,000	1,253,000	199,000	398,000	398,000	398,000	502,000	816,000	1,129,000		1,253,000	1,253,000	1,253,000	1,253,000	1,253,000	1,253,000	1,253,000	1,253,000	1,148,000	868,000
secured loan, less current portion																																									9,208,000	11,809,000	13,104,000	14,216,000		100,000	199,000	398,000	498,000	597,000		104,000	418,000	731,000	1,044,000	1,357,000	1,670,000	1,983,000	2,296,000	2,610,000	1,987,000
accumulated other comprehensive loss																																																				-25,000	-14,000
property and equipment, less accumulated depreciation of 12,381 and 11,520 at june 30, 2015 and december 31, 2014, respectively																																								3,379,000
accumulated other comprehensive income																																										2,000		2,000	5,000	3,000	15,000	37,000	17,000	37,000				1,000	-28,000	11,000	6,000	2,000	43,000	88,000	145,000	234,000	533,000	68,000	318,000	930,000	408,000	220,000	113,000
property and equipment, less accumulated depreciation of 12,028 and 11,520 at march 31, 2015 and december 31, 2014, respectively																																									3,056,000
receivable due from collaboration agreements																																										293,000	475,000
property and equipment, less accumulated depreciation and amortization of 9,973 and 11,157 at december 31, 2013 and september 30, 2014, respectively																																										3,129,000
property and equipment, less accumulated depreciation and amortization of 9,973 and 10,781 at december 31, 2013 and june 30, 2014, respectively																																											3,444,000
receivable due from gsk																																												38,000	2,121,000	1,024,000	1,308,000	3,184,000	7,237,000	4,301,000		3,828,000	1,977,000	3,969,000
property and equipment, less accumulated depreciation and amortization of 9,973 and 10,385 at december 31, 2013 and march 31, 2014, respectively																																												3,748,000
deficit accumulated during the development stage																																																			-270,104,000	-261,442,000	-251,683,000	-239,042,000	-225,692,000	-210,604,000	-195,247,000	-183,932,000	-170,756,000	-203,712,000	-190,283,000	-176,661,000	-164,189,000	-150,039,000	-141,859,000	-132,565,000	-124,834,000	-113,061,000	-102,758,000	-83,667,000
property and equipment, less accumulated depreciation and amortization of 8,501 and 9,751 at december 31, 2012 and september 30, 2013, respectively																																													4,356,000
warrant liability																																													34,000	551,000	1,170,000	3,889,000	4,442,000	4,324,000		2,690,000	6,066,000	8,144,000	4,712,000	3,766,000	1,707,000	3,098,000
warrant liability, non-current
property and equipment, less accumulated depreciation and amortization of 8,501 and 9,321 at december 31, 2012 and june 30, 2013, respectively																																														4,715,000
property and equipment, less accumulated depreciation and amortization of 8,501 and 8,872 at december 31, 2012 and march 31, 2013, respectively																																															4,962,000
property and equipment, less accumulated depreciation and amortization of 9,507 and 8,080 at december 31, 2011 and september 30, 2012, respectively																																																5,293,000
current portion of deferred reimbursements
deferred reimbursements, less current portion																																																27,235,000
property and equipment, less accumulated depreciation and amortization of 9,507 and 7,658 at december 31, 2011 and june 30, 2012, respectively																																																	5,489,000
current portion of deferred revenue																																																	7,929,000	8,187,000		9,274,000	8,606,000	7,965,000	6,640,000					2,778,000	2,778,000	3,176,000	3,705,000	4,043,000	3,295,000	4,612,000	3,801,000
deferred revenue, less current portion																																																	15,679,000	17,339,000		20,659,000	22,319,000	23,979,000	25,639,000					41,952,000	42,647,000	43,341,000	44,035,000	44,730,000	45,424,000	46,119,000	46,813,000
property and equipment, less accumulated depreciation and amortization of 9,507 and 7,216 at december 31, 2011 and march 31, 2012, respectively																																																		5,073,000
balance sheet data:
cash and cash equivalents and marketable securities																																																			55,702,000																			54,699,000
working capital																																																			47,392,000																			44,814,000
redeemable convertible preferred stock																																																																						124,089,000
property and equipment, accumulated depreciation and amortization of 8,095 and 9,338 at december 31, 2010 and september 30, 2011, respectively																																																				1,759,000
current portion of capital lease obligations																																																							40,000	86,000	142,000	227,000	305,000	397,000	603,000	695,000	877,000	1,090,000	1,258,000	1,420,000	1,527,000	1,521,000	1,504,000
property and equipment, accumulated depreciation and amortization of 8,095 and 8,959 at december 31, 2010 and june 30, 2011, respectively																																																					1,922,000
property and equipment, less accumulated depreciation and amortization of 8,095 and 8,533 at december 31, 2010 and march 31, 2011, respectively																																																						2,237,000
property and equipment, less accumulated depreciation and amortization of 6,340 and 8,095 at december 31, 2009 and 2010, respectively																																																							2,604,000
capital lease obligations, less current portion																																																										24,000	48,000	86,000	164,000	223,000	317,000	483,000	695,000	918,000	1,194,000	1,573,000	1,953,000
property and equipment, less accumulated depreciation and amortization of 6,340 and 7,917 at december 31, 2009 and september 30, 2010, respectively																																																								3,017,000
property and equipment, less accumulated depreciation and amortization of 6,340 and 7,406 at december 31, 2009 and june 30, 2010, respectively																																																									3,472,000
property and equipment, less accumulated depreciation and amortization of 6,340 and 6,877 at december 31, 2009 and march 31, 2010, respectively																																																										3,934,000
property and equipment, less accumulated depreciation and amortization of 4,260 and 6,340 at december 31, 2008 and 2009, respectively																																																											4,399,000
property and equipment, less accumulated depreciation and amortization of 4,260 and 5,832 at december 31, 2008 and september 30, 2009, respectively																																																												5,049,000
property and equipment, less accumulated depreciation and amortization of 4,260 and 5,271 at december 31, 2008 and june 30, 2009, respectively																																																													5,326,000
property and equipment, less accumulated depreciation and amortization of 4,260 and 4,762 at december 31, 2008 and march 31, 2009, respectively																																																														5,076,000
property and equipment, less accumulated depreciation and amortization of 2,793 and 4,260 at december 31, 2007 and 2008, respectively																																																															4,919,000
property and equipment, less accumulated depreciation and amortization of 2,793 and 3,804 at december 31, 2007 and september 30, 2008, respectively																																																																4,416,000
property and equipment, less accumulated depreciation and amortization of 2,793 and 3,421 at december 31, 2007 and june 30, 2008, respectively																																																																	4,195,000
property and equipment, less accumulated depreciation and amortization of 2,793 and 3,114 at december 31, 2007 and march 31, 2008, respectively																																																																		3,631,000
accrued expenses																																																																		7,728,000	9,935,000	7,515,000	5,123,000
stockholders’equity:
property and equipment, less accumulated depreciation and amortization of 1,557 and 2,793 at december 31, 2006 and 2007, respectively																																																																			3,790,000
liabilities and stockholders’ (deficiency) equity
series a redeemable convertible preferred stock, .01 par value...
series b redeemable convertible preferred stock, .01 par value...
series c redeemable convertible preferred stock, .01 par value...
series d redeemable convertible preferred stock, .01 par value...
stockholders’ (deficiency) equity:
total stockholders’ (deficiency) equity																																																																			103,297,000	113,689,000	122,665,000	-77,515,000
total liabilities and stockholders’ (deficiency) equity																																																																			167,097,000
property and equipment, less accumulated depreciation and amortization of 1,557 and 2,478 at december 31, 2006 and september 30, 2007, respectively																																																																				3,913,000
property and equipment, less accumulated depreciation and amortization of 1,557 and 2,166 at december 31, 2006 and june 30, 2007, respectively																																																																					4,161,000

Cashflow Statements:

Quarterly

Annual

Unit: USD	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-09-30	2017-06-30	2017-03-31	2016-06-30	2016-03-31	2015-06-30	2015-03-31	2014-06-30	2013-06-30	2013-03-31	2012-06-30	2012-03-31	2011-12-31	2011-06-30	2010-12-31	2010-03-31	2009-12-31	2009-06-30	2009-03-31	2007-09-30

operating activities
net loss	1,690,000	17,306,000	-24,420,000	-21,686,000	14,739,000	-6,729,000	-15,697,000	-48,419,000	-33,843,000	-21,577,000	-43,232,000	-52,932,000	-55,865,000	-33,286,000	-62,157,000	-85,260,000	-83,277,000	-50,294,000	-51,225,000	-65,664,000	-71,401,000	-64,011,000	-52,492,000	-88,948,000	-89,729,000	-61,809,000	-84,551,000	-120,299,000	-78,081,000	-159,163,000	-61,835,000	-49,916,000	-111,665,000	-48,137,000	-54,992,000	-94,741,000	-43,691,000	-51,421,000	-24,288,000	-30,557,000	-32,807,000	-17,458,000	-22,480,000	-13,137,000	-8,662,000	-25,991,000	-15,088,000	-13,176,000	32,956,000	-26,095,000	-12,472,000	-10,303,000
adjustments to reconcile net loss to net cash from operating activities:
amortization of debt discount and deferred financing	676,000	658,000	630,000	606,000	597,000	574,000	560,000	531,000	536,000	721,000	692,000	667,000	671,000	668,000	658,000	637,000	638,000	652,000	645,000	555,000	670,000	592,000	301,000	231,000	256,000	186,000	455,000	1,649,000	3,108,000	2,595,000	2,672,000	2,601,000
depreciation and amortization	1,897,000	1,874,000	1,852,000	1,837,000	2,041,000	2,170,000	2,182,000	2,154,000	2,182,000	2,228,000	2,206,000	1,257,000	1,311,000	1,286,000	1,334,000	1,411,000	1,518,000	1,520,000	1,567,000	1,604,000	2,547,000	2,496,000	2,039,000	1,764,000	1,514,000	1,116,000	1,154,000	991,000												808,000	889,000	439,000	862,000	420,000	342,000	864,000	481,000	536,000	547,000	1,024,000	505,000	315,000
stock-based compensation	26,590,000	18,089,000	17,559,000	25,172,000	19,217,000	18,688,000	16,197,000	30,803,000	18,095,000	16,511,000	16,577,000	34,894,000		14,772,000	12,463,000	30,651,000	13,907,000	11,841,000	11,736,000	20,354,000	12,239,000	15,908,000	8,408,000	12,596,000	12,908,000	8,843,000	9,935,000	12,744,000	8,387,000	7,054,000	6,341,000	7,478,000	5,500,000	5,537,000	6,030,000	8,748,000	4,283,000	4,191,000	1,960,000	2,748,000
loss on extinguishment of debt																	0				0																	952,000
non-cash changes in the fair value of contingent consideration payable									0	1,995,000	337,000	251,000	1,584,000	567,000	115,000	-1,188,000	1,734,000	3,288,000	1,021,000	471,000	464,000	1,034,000	715,000	931,000	645,000	789,000	480,000	1,383,000	600,000	1,300,000	300,000	1,100,000		1,050,000	4,578,000	13,338,000	3,152,000	1,100,000	1,000,000	200,000
foreign currency remeasurement loss	-3,622,000	8,453,000	4,111,000	-5,356,000	1,067,000	5,776,000	7,655,000	1,736,000	1,492,000	-5,783,000	18,019,000	5,885,000	3,293,000	2,475,000	-320,000	673,000	-682,000	1,012,000	389,000	2,846,000	6,555,000	-6,688,000	-5,058,000	10,662,000	-2,411,000	2,135,000	205,000	325,000	2,442,000	-1,332,000						1,892,000
non-cash deferred taxes																																		49,000	49,000
asset impairment charges and other write-offs
changes in operating assets and liabilities:
accounts receivable	-614,000	-8,084,000	-12,492,000	15,330,000	-10,394,000	-8,643,000	-10,004,000	9,557,000	-11,494,000	-11,319,000	4,072,000	-1,367,000	-9,904,000	-3,002,000	-3,424,000	-1,000,000	-1,817,000	-3,245,000	-3,966,000	839,000	-374,000	-457,000	-2,030,000	-8,358,000	1,530,000	-5,815,000	-5,828,000	-1,001,000	-8,112,000	861,000
inventories	-44,296,000	-36,322,000	-22,577,000	-8,288,000	-12,020,000	-34,731,000	-25,223,000	-1,678,000	-2,381,000	-14,750,000	-24,325,000	-3,158,000	-10,256,000	1,376,000	1,725,000	1,812,000	-4,768,000	1,423,000	-5,186,000	741,000	-6,821,000	831,000	1,602,000	-251,000	-3,098,000	-108,000	-2,253,000	345,000	-2,156,000	1,400,000
prepaid expenses and other current assets	-595,000	7,570,000	-4,754,000	-3,603,000	-14,255,000	14,257,000	19,299,000	-5,340,000	17,948,000	-13,747,000	-14,102,000	1,839,000	-611,000	-1,102,000	-7,813,000	3,332,000	-14,999,000	3,815,000	-2,404,000	7,669,000	-13,143,000	3,002,000	-2,641,000	4,016,000	34,000	202,000	-6,582,000	3,059,000	-145,000	-1,951,000	-6,291,000	10,875,000						641,000	418,000	4,245,000	292,000	517,000	3,245,000	3,114,000	963,000	-2,817,000	661,000	-242,000	2,043,000	-189,000	479,000	187,000
accounts payable, accrued expenses, and other current liabilities	38,143,000	30,627,000	10,360,000	3,647,000	-5,037,000	-14,124,000	27,124,000	-24,483,000	8,094,000	9,481,000	31,692,000	-72,000	-31,842,000	2,794,000	37,234,000	-14,563,000
other non-current assets and liabilities	656,000	-3,676,000	411,000	-1,076,000	-2,033,000	-737,000	-104,000	-374,000	1,939,000	-2,407,000	-2,192,000	-394,000	1,306,000	-3,180,000	-1,326,000	-1,436,000	-447,000	-386,000	-206,000	-1,578,000	6,684,000	-1,233,000	4,303,000	-5,334,000	-12,081,000	2,783,000	2,688,000	-3,507,000
payment of contingent consideration									-13,410,000	0
net cash from operating activities	16,253,000	35,660,000	-26,526,000	7,758,000	-3,916,000	-22,971,000	22,691,000	-29,695,000	3,458,000	-38,347,000	-16,133,000	-18,069,000	-80,772,000	-11,626,000	-15,862,000	-58,315,000	-70,514,000	-23,700,000	-35,923,000	-72,354,000	-49,822,000	-42,008,000	-33,518,000	-107,942,000	-57,832,000	-55,553,000	-58,485,000	-78,546,000	-60,677,000	-132,762,000	-56,995,000	-49,521,000													-12,521,000	-23,913,000	22,365,000	-13,429,000	-10,592,000	-21,305,000	-10,850,000	-6,104,000
investing activities
sale and redemption of marketable securities	16,857,000	17,256,000	10,995,000	6,161,000	15,904,000	39,540,000	23,428,000	38,907,000	16,399,000	53,980,000	71,904,000	54,944,000	76,006,000	75,859,000	75,733,000	108,328,000	81,700,000	83,576,000	95,087,000	163,680,000	82,147,000	62,540,000	103,999,000	106,140,000	109,805,000	127,817,000	126,238,000	135,187,000	75,367,000	177,896,000	89,013,000	121,226,000	93,072,000	68,466,000	69,443,000	121,283,000	53,157,000	63,163,000	40,739,000	31,114,000	42,434,000	34,135,000	34,839,000	14,300,000	20,219,000	57,224,000	17,167,000	19,771,000	25,393,000	76,926,000	45,462,000	27,468,000
purchases of marketable securities	-23,052,000	-18,173,000	-14,370,000	-38,810,000	-36,008,000	-4,912,000	-44,307,000	-29,559,000	-38,625,000	-16,650,000	-19,701,000	-16,747,000	-143,444,000	-1,481,000	-49,086,000	-49,244,000	-148,029,000	-48,114,000	-69,008,000	-76,247,000	-103,856,000	-216,317,000	-32,917,000	-12,088,000	-71,917,000	-120,647,000	-139,140,000	-52,178,000	-137,431,000	-60,729,000															-3,505,000	-36,594,000	-59,595,000	-8,799,000	-15,539,000	-68,933,000	-38,516,000	-27,606,000
capital expenditures	-299,000	-382,000	-2,403,000	-212,000	-288,000	-356,000	-1,098,000	-1,811,000	-1,731,000	-1,565,000	-2,202,000	-1,942,000	-2,677,000	137,000	-355,000	-871,000	-1,760,000	-890,000	-366,000	-868,000	-1,067,000	-284,000	-1,070,000	-806,000	-10,925,000	-3,977,000	-2,166,000	-2,944,000	-1,737,000	-2,690,000	0	0													-1,022,000	-182,000	-189,000	-69,000	-83,000	-1,440,000	-665,000	-67,000
free cash flows	15,954,000	35,278,000	-28,929,000	7,546,000	-4,204,000	-23,327,000	21,593,000	-31,506,000	1,727,000	-39,912,000	-18,335,000	-20,011,000	-83,449,000	-11,489,000	-16,217,000	-59,186,000	-72,274,000	-24,590,000	-36,289,000	-73,222,000	-50,889,000	-42,292,000	-34,588,000	-108,748,000	-68,757,000	-59,530,000	-60,651,000	-81,490,000	-62,414,000	-135,452,000	-56,995,000	-49,521,000													-13,543,000	-24,095,000	22,176,000	-13,498,000	-10,675,000	-22,745,000	-11,515,000	-6,171,000
net cash from investing activities	-6,494,000	-1,299,000	-5,778,000	-32,861,000	-20,392,000	34,272,000	-21,977,000	7,537,000	-23,957,000	35,765,000	50,001,000	36,255,000	-66,704,000	74,515,000	26,292,000	58,213,000	-68,089,000	34,572,000	25,713,000	86,565,000	-22,776,000	-154,061,000	70,012,000	93,246,000	26,963,000	3,193,000	-15,068,000	80,065,000	-63,801,000	114,477,000	10,727,000	-182,603,000							21,665,000	2,133,000		6,765,000			15,692,000	20,448,000		10,903,000	9,771,000	6,553,000	6,281,000	-205,000
financing activities
proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs					413,000				0	36,555,000	24,199,000	2,354,000
proceeds from equity financing, net of issuance costs
withholding taxes paid on vested restricted stock units	-4,460,000	-1,641,000	-432,000	-11,790,000	-828,000	-2,792,000	-1,684,000	-16,721,000	-1,565,000	-2,347,000
proceeds from stock options exercised	18,721,000	339,000	40,000	105,000	1,555,000	1,805,000	863,000	3,454,000	2,414,000	3,442,000	1,750,000	2,655,000	1,119,000	1,333,000	999,000	859,000	1,871,000	1,696,000
proceeds from warrants exercised									0	0							0	0
payment of long-term debt																					0
proceeds from long-term debt, net of issuance costs																					0
payment of finance leases	-232,000	-17,000	-8,000	-15,000	-43,000	24,000	-36,000	-42,000	-193,000	-31,000	-23,000	-28,000	-191,000	-51,000	-21,000	-20,000	-19,000	-71,000	-21,000	-368,000	-18,000	-20,000	-17,000	-21,000	-243,000	-79,000	-23,000	-75,000
net cash from financing activities	14,029,000	-1,319,000	-400,000	-11,700,000	1,097,000	18,190,000	-857,000	-13,309,000	8,210,000	37,619,000	23,673,000	-7,825,000	557,000	-559,000	693,000	-8,154,000	-104,000	201,113,000	2,235,000	8,829,000	21,548,000	238,711,000	4,086,000	-1,487,000	3,191,000	523,000	196,404,000	17,384,000	359,000	146,804,000									4,000	18,170,000					-313,000	-318,000	27,727,000	16,749,000	-327,000	2,439,000	-262,000	-252,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash	-329,000	-1,200,000	9,987,000	4,819,000	3,107,000	-5,028,000	-294,000	-1,816,000	-3,906,000	16,902,000	-8,191,000	1,507,000	18,501,000	-20,658,000	-9,085,000	-3,377,000	-908,000	-2,702,000	-286,000	-1,153,000	3,785,000	3,521,000	789,000	-4,265,000	4,320,000	-1,650,000
net increase in cash, cash equivalents, and restricted cash																									-23,358,000	-53,487,000
cash, cash equivalents, and restricted cash at the beginning of the year
cash, cash equivalents, and restricted cash at the end of the year
other		-835,000	2,794,000	1,175,000		528,000	702,000	5,818,000																	-13,000
net decrease in cash, cash equivalents, and restricted cash at the end of the period		31,842,000	-22,717,000	-31,984,000
cash, cash equivalents, and restricted cash at the beginning of period		0	0	216,716,000		0	0	250,077,000		0	0	153,115,000		0	0	249,456,000
cash, cash equivalents, and restricted cash at the end of period		31,842,000	-22,717,000	184,732,000		24,463,000	-437,000	212,794,000		51,939,000	49,350,000	164,983,000		41,672,000	2,038,000	237,823,000		209,283,000	-8,261,000	188,049,000		46,163,000	41,369,000	125,893,000
supplemental disclosures of cash flow information
cash paid during the period for interest		11,058,000	10,942,000	10,852,000		23,797,000	11,989,000	11,801,000		12,293,000	11,794,000	11,361,000		8,950,000	7,599,000	7,509,000	7,680,000	7,679,000	7,596,000	7,513,000		6,003,000	7,016,000	3,693,000		3,843,000	4,456,000	4,846,000	3,713,000	13,000	3,762,000	12,000	12,000	3,638,000	12,000	276,000		605,000	209,000	537,000									95,000	71,000	29,000	89,000
cash paid for taxes		1,614,000	354,000	377,000		1,603,000	491,000	635,000		495,000	5,800,000	178,000		225,000	254,000	456,000	10,178,000	5,328,000	2,054,000	2,472,000
supplemental disclosure of non-cash investing and financing activities
tenant improvements paid through lease incentives		97,000	98,000	97,000		97,000	68,000	52,000										0				15,000	201,000	254,000
capital expenditures unpaid at the end of period			36,000	138,000		78,000	-1,020,000	1,110,000		580,000	-963,000	1,260,000		0	-19,000	72,000	1,121,000	136,000	3,000	188,000		-237,000	-87,000	589,000
cashless exercise of warrants		0	0	71,000
asset impairment charges and other asset write-offs									367,000	300,000			906,000	5,006,000
proceeds from sale of assets
deferred taxes										0	0	-4,939,000
net increase in cash, cash equivalents, and restricted cash at the end of the period						24,463,000	-437,000	-37,283,000		51,939,000	49,350,000	11,868,000		41,672,000	2,038,000	-11,633,000		209,283,000	-8,261,000	21,887,000		46,163,000	41,369,000	-20,448,000
purchase of vested restricted stock units, net of taxes												-12,806,000	-371,000	-1,841,000	-285,000	-8,993,000
share-based compensation
proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs
loss on impairment of assets																6,616,000
loss on exchange of convertible notes
deferred reimbursements																					0				-4,000,000	0	0	-1,500,000													2,291,000	1,267,000
proceeds from issuance of common stock, net of issuance costs																										0				0	0	294,584,000				57,818,000		243,216,000		18,344,000
payments of employee withholding taxes related to restricted stock unit vesting																	-309,000	-262,000
proceeds from termination of capped call confirmations																									0	0	5,243,000	14,632,000
tenant improvements paid through lease incentive
contingent consideration paid in shares
accounts payable and accrued expenses																		6,417,000	11,706,000	-40,191,000		492,000	11,335,000	-35,251,000		-3,739,000	21,311,000	-8,858,000										459,000			173,000					-1,271,000		-2,277,000		2,193,000	-113,000	2,589,000
proceeds from issuance of common stock from equity financing and pre-funded warrants
cash, cash equivalents, and restricted cash at beginning of period																		0	0	166,162,000		0	0	146,341,000		0
purchase of vested restricted stock units																				-14,194,000	-688,000	-1,243,000	-554,000	-7,543,000	-234,000	-446,000	-617,000	-1,938,000	-151,000	-654,000
proceeds from exercise of stock options																				4,161,000	22,254,000	9,294,000	4,657,000	6,077,000	3,668,000	1,048,000	2,807,000	3,953,000	652,000	912,000	3,602,000	3,978,000	7,287,000	1,289,000	265,000	647,000	155,000	6,932,000	4,063,000	25,000			840,000	837,000	0	348,000	3,000	11,000	12,000	11,000	14,000	112,000
proceeds from exercise of warrants																				19,230,000									0									4,000,000														0
change in fair value of derivatives																													0	0
loss on exchange of convertible debt																									0	0	4,501,000	36,123,000
proceeds of exercise of warrants																										0	0	812,000
loss on impairment
proceeds from issuance of common stock and warrants, net of issuance costs
proceeds from loan agreements, net of issuance costs
proceeds from senior secured term loan
cash, cash equivalents, and restricted cash at end of period																										-53,487,000
capital expenditures, unpaid																										1,965,000						142,000
payment of contingent consideration in shares																										0	0	9,316,000
capital expenditures funded by capital lease																														-1,000
effect of exchange rate changes on cash, cash equivalents and restricted cash																												-2,350,000	2,664,000	-130,000
net decrease in cash, cash equivalents and restricted cash																												16,553,000
cash, cash equivalents and restricted cash at beginning of period																												82,375,000
cash, cash equivalents and restricted cash at end of period																												98,928,000
depreciation																													1,201,000	1,073,000	973,000	969,000	850,000	813,000	823,000	1,440,000	673,000	861,000	508,000
restructuring charges																																				58,000	50,000	36,000	10,000
charges to research expense for stock issued in asset acquisition
loss on disposal of assets
other non-current assets																													62,000	-308,000										25,000			267,000	267,000	5,000		0	218,000
account payable and accrued expenses																													13,431,000	15,485,000
non-current liabilities																													-223,000	224,000	237,000	220,000	141,000	133,000	363,000	535,000	380,000		282,000	14,000
payments of secured loan agreement																																													-313,000	-626,000	-313,000	-313,000
payment of capital leases																													-116,000	-76,000
proceeds from issuance of convertible notes, net of issuance costs
premiums paid for capped call confirmations
net increase in cash and cash equivalents and restricted cash																													-121,455,000	128,389,000	-41,111,000	65,315,000
cash and cash equivalents and restricted cash at beginning of year/period
cash and cash equivalents and restricted cash at end of year/period
capital expenditures funded by capital lease borrowings																																				850,000
gain on disposal of asset
deferred reimbursement																														0
proceeds from senior secured term loan, net of issuance costs
payment of deferred financing fees
cash and cash equivalents and restricted cash at beginning of period																														0	0	51,237,000
cash and cash equivalents and restricted cash at end of period																														128,389,000	-41,111,000	116,552,000
foreign currency remeasurement gain
net cash provided by financing activities																																296,579,000				82,761,000		237,240,000
effect of exchange rate changes on cash and cash equivalents and restricted cash																																860,000
loss on disposal of asset																																				17,000							27,000	27,000					186,000	9,000	2,000
change in fair value of derivative liability
non-cash deferred taxes and other tax benefits
purchases of property and equipment																																													-1,022,000	-182,000	-189,000	-69,000	-83,000	-1,440,000	-665,000	-67,000
proceeds from unsecured loan agreement
effect of exchange rate changes on cash and cash equivalents																																	416,000	534,000	80,000
net decrease in cash and cash equivalents
cash and cash equivalents at beginning of year/ period																																	0	0	187,026,000
cash and cash equivalents at end of year/period																																	26,739,000	-7,361,000	44,755,000
contingent consideration resolution in shares																																				6,115,000
non-cash interest expense																																		2,312,000	2,403,000	1,014,000	451,000	136,000	83,000	115,000
non-cash income tax benefit
net cash used in/ (provided by) financing activities
capital expenditures unpaid at end of the period
non-cash changes in the fair value of derivative liability																																				346,000
acquisitions, net cash of acquired
proceeds from unsecured note agreement																																				30,000,000
proceeds from related party
payment of capital lease
cash and cash equivalents at beginning of period																																				69,485,000	69,485,000	24,074,000	24,074,000	43,640,000	33,971,000	33,971,000	25,668,000	25,668,000		29,572,000		19,339,000		28,073,000	28,073,000	0
cash and cash equivalents at end of period																																				63,656,000	23,510,000	249,023,000	28,827,000	41,904,000	23,476,000	26,736,000	28,858,000	24,523,000		25,789,000		33,562,000		15,760,000	23,242,000	-6,561,000
net cash (used in)/ provided by investing activities																																									13,865,000
net (decrease)/ increase in cash and cash equivalents
net cash (used in)/ provided by financing activities
receivable due from collaboration agreements																																								607,000
net cash (used in) investing activities
net cash provided by investing activities																																						31,320,000
net increase in cash and cash equivalents																																						224,949,000	4,753,000				3,190,000		2,858,000	-3,783,000	7,475,000	14,223,000	-1,148,000	-12,313,000	-4,831,000	-6,561,000
adjustments to reconcile net loss to net cash used in operating activities:
change in fair value of warrant liability																																										262,000	2,494,000	2,376,000	-742,000	1,354,000	946,000	-204,000				0
non-cash activities
net income
adjustments to reconcile net income to net cash from operating activities:
amortization of non-cash compensation
non-cash charge for stock based compensation issued to consultants
stock-based license payments
impairment of leasehold improvements
non-cash charge for in-process research and development
beneficial conversion feature related to bridge financing
receivable due from gsk
net cash provided by/(used in) investing activities
proceeds from the issuance of preferred stock, net of issuance costs																																																				0
proceeds from the issuance of common stock and warrants, net of issuance costs																																											62,057,000	62,063,000				17,153,000
proceeds from the issuance of convertible notes
payments of capital lease obligations																																													0	-40,000	-46,000	-102,000	-130,000	-427,000	-276,000	-364,000
payments related to deferred financing
proceeds from capital asset financing arrangement																																																				0
proceeds from secured loan agreement																																											995,000	995,000
net cash (used in)/provided by financing activities																																												63,582,000
net (decrease)/increase in cash and cash equivalents
stock-based compensation - employees																																									3,157,000	1,574,000	3,145,000	1,388,000
stock-based compensation - non-employees
redemption of marketable securities
proceeds from secured loan arrangement																																																		2,855,000
net cash from/ (used in) financing activities
receivable from gsk																																									2,201,000	1,917,000		742,000
net cash (used in)/provided by investing activities
net cash provided by/(used in) financing activities
debt instrument convertible beneficial conversion feature
net cash from/(used in) investing activities
net cash (used in) /provided by financing activities																																											63,166,000
conversion of notes payable to preferred stock
conversion of preferred stock to common stock																																																				0
accretion of redeemable convertible preferred stock																																																				0
beneficial conversion feature related to the issuance of series c redeemable convertible preferred stock
deferred revenue																																													-2,430,000	-1,354,000			-44,730,000	-2,316,000	-1,223,000
stock-based license payment
non-cash charge for in process research and development
conversion of notes payable to series b redeemable convertible preferred stock
beneficial conversion feature related to issuance of the additional issuance of series c redeemable convertible preferred stock
stock-based compensation — employees																																														5,302,000		1,716,000		4,069,000	1,972,000	1,080,000
stock-based compensation — non-employees																																																				28,000
net increase/(decrease) in cash and cash equivalents
net cash provided/(used in) by investing activities
proceeds from the issuance of common stock, net of issuance costs																																																				0
beneficial conversion feature related to the issuance
of series c redeemable convertible preferred stock
adjustments to reconcile net income to net cash (used in)/provided by operating activities:
net cash provided by/(used in) operating activities
payments from exercise of stock options
beneficial conversion feature related to issuance of the second tranche of series c redeemable convertible preferred stock
warrant issued with convertible notes
warrant issued with series b redeemable convertible preferred stock

Amicus Therapeutics, Inc(NASDAQ:FOLD)

Amicus Therapeutics, Inc
(NASDAQ:FOLD)